Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Idris, Sherif; Lindsay, Cameron; Kostiuk, Morris; Andrews, Colin; Côté, David; O'Connell, Daniel; Harris, Jeffrey; Seikaly, Hadi; Biron, Vincent
• Is Part Of: Journal of otolaryngology - head & neck surgery. Volume 45:Issue 1(2016)
• Page Start: 1
• Page End: 7
• Publication Date: 2016-12
• Subjects: Epigenetics -- EZH2 -- Histone methylation -- Oropharyngeal cancer -- Squamous cell carcinoma -- GSK-343 -- 3-deazaneplanocin A -- EPZ005687; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; Otorhinolaryngologic Surgical Procedures -- Periodicals; Head -- Surgery; Neck -- Surgery; Otolaryngology; Periodicals; 617.51005
• DOI: 10.1186/s40463-016-0168-9
• Languages: English
• ISSNs: 1916-0208

Abstract

Abstract Background In recent decades, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been rising worldwide as a result of increasing oncogenic human papillomavirus (HPV) infections in the oropharynx. EZH2 is an epigenetic regulatory protein associated with tumor aggressiveness and negative survival outcomes in several human cancers. We aimed to determine the role of EZH2 as a potential therapeutic epigenetic target in HPV-positive and negative OPSCC. Methods The expression of EZH2 was measured by immunohistochemistry (IHC) and droplet digital PCR (ddPCR) in 2 HPV-positive and 2 HPV-negative cell lines. The cell lines were then cultured and treated with one of 3 EZH2 epigenetic inhibitors (3-deazaneplanocin A, GSK-343 and EPZ005687) or DMSO (control). Following 2, 4 and 7 days of treatment, cells were analyzed and compared by gene expression, cell survival and proliferation assays. Results EZH2 targeting resulted in greater inhibition of growth and survival in HPV-positive compared to HPV-negative cells lines. The expression profile of genes important in OPSCC also differed according to HPV-positivity for Ki67, CCND1, MET and PTEN/PIK3CA, but remained unchanged for EGFR, CDKN2A and p53. Conclusion Inhibition of EZH2 has anti-tumorigenic effects on OPSCC cells in culture that is more pronounced in HPV-positive cell lines. EZH2 is a promising epigenetic target for the treatment of OPSCC.